Latest News

Latest News

Resource spotlight: Cystic Fibrosis

December 5, 2022
 

Written by Duaa Osman

This article was written and researched by a CSHP student member for Interactions, our biweekly newsletter. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the student to select topics that are of interest and utility to both the student and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think: If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca


Background

Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused by a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein resulting in abnormal ion transport across cell membranes, affecting multiple organ systems such as the pulmonary, reproductive, and digestive systems. According to the Canadian Cystic Fibrosis Registry 2020 annual report, a total of 4,332 Canadians are affected by CF attributing to 1 in every 3,600 live births. Early diagnosis and treatment of CF is a crucial component of long-term survival. This “Resource Spotlight” contains links to associations, guidelines and studies that help pharmacists learn more about cystic fibrosis and its management, along with helpful resources to share with patients. To learn more about cystic fibrosis, check out CSHP’s recent Clinical Pearls article on Cystic Fibrosis

External Resources 

Unless otherwise noted, the Canadian Society of Hospital Pharmacists (CSHP) does not endorse or imply endorsement of the resources provided here. These resources are provided without warranty of any kind, either expressed or implied. It is the responsibility of the user of the resource to judge its suitability for his or her particular purpose within the context of his or her practice and the applicable legislative framework. In no event shall CSHP or any persons involved in providing the resource be liable for damages arising from its use. Resources are free unless otherwise indicated. 

Cystic fibrosis Canada

Cystic fibrosis Canada is a non-profit organization committed to supporting patients with cystic fibrosis. The organization provides useful resources to patients with CF, caregivers, and healthcare professionals. Healthcare providers can make use of the organization’s published guidelines concerning the treatment and management of CF such as the Canadian Clinical Consensus Guideline for Initiation, Monitoring and Discontinuation of CFTR Modulator Therapies for Patients with Cystic Fibrosis, as well as Antibiotic Dosing Guidelines for Cystic Fibrosis. Each year, Cystic Fibrosis Canada publishes a report surveying CF patient data across Canada to provide a snapshot of CF care across the nation. The data from these reports helps healthcare providers and researchers gain knowledge which can be used to help improve health outcomes for patients with CF. In addition, their clinical trials network, Cystic Fibrosis Canada Accelerating Clinical Trials (CF CanACT), can be used to easily search for ongoing clinical trials and eligibility criteria for enrollment. 

The management of CF can be overwhelming for patients and caregivers as the disease can affect a multitude of organ systems. To support patients and caregivers, Cystic Fibrosis Canada also provides patient-friendly resources on topics such as transitioning from pediatric to adult care, parenting with CF, supporting students in schools, and general health recommendations. An email helpline (helpline@cysticfibrosis.ca) is also available to connect patients with staff at Cystic Fibrosis Canada.

In addition, each year, Cystic Fibrosis Canada hosts the Walk to Make Cystic Fibrosis History event which aims to raise funds to support the care of patients diagnosed with CF. The overall goal is to help improve health outcomes by improving access to CF medications, advancing research efforts, and improving the overall quality of CF care provided in Canada. 

Government of British Columbia

In 2018, the government of British Columbia’s Ministry of Health released guidelines on Standards of Care and Nutrition Management for patients with CF. The Standards of Care guideline outlines recommendations for patient care in both inpatient and outpatient settings, infection prevention and control measures, as well as the role pharmacists play in interdisciplinary CF care teams. The nutritional management guideline can act as a useful tool for pharmacists when assessing a CF patient’s nutritional support with respect to vitamin supplementation. It provides recommendations on types of supplements, dosing, and monitoring parameters. The BC Ministry of Health also provides a webpage on CF describing the condition and treatment options in patient-friendly language.

To support COVID-19 vaccination efforts for patients with CF, the ministry has also released a COVID-19 clinical guidance document outlining available evidence relating to safety and efficacy of the COVID-19 vaccine along with the risk factors of COVID-19 infection in patients with CF. 

Current literature

European Cystic Fibrosis Society best practice guidelines1  revised in 2018, provide an overview of cystic fibrosis newborn screening, diagnosis, treatments -including treatment of bacterial infections, nutritional supports, and complications. 

An article by Bierlaagh et al2, also provides an update on treatments for CF, specifically developments related to CFTR modulator therapies. CFTR modulators are a class of medication that aims to partially restore CFTR function by targeting underlying genetic mutations found in patients with CF. Available modulator therapies can potentially work to limit the progression and expression of cystic fibrosis. 

As therapeutic options for the management of CF continue to advance, and life expectancies continue to increase, there has been an observed increase in the number of patients with CF who have successful pregnancies. Pregnancies in patients with CF have several clinical considerations which are discussed in this article by Montemayor et al.These considerations include preconception health optimization, medication management during pregnancy and lactation, and considerations for treatment of pulmonary exacerbation in pregnant patients.

References 

1. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-178. doi:10.1016/j.jcf.2018.02.006
2. Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK. A new era for people with cystic fibrosis. Eur J Pediatr. 2021;180(9):2731-2739. doi:10.1007/s00431-021-04168-y
3. Montemayor K, Tullis E, Jain R, Taylor-Cousar JL. Management of pregnancy in cystic fibrosis. Breathe (Sheff). 2022;18(2):220005. doi:10.1183/20734735.0005-2022

 

 

December 05, 2022
Resource spotlight: Cystic Fibrosis

Clinical Pearls: Cystic Fibrosis 

November 21, 2022
By Duaa Osman

This article is part of a series appearing in Interactions, our biweekly newsletter, written and researched by CSHP's students. We've created this series as a valuable learning activity for pharmacy students undertaking rotations at CSHP. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the students to select hot topics that are of interest and utility to both the students and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think: If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca.

Background

Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused by a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein resulting in abnormal ion transport across cell membranes.This altered ion transport causes CF to affect multiple organ systems such as the pulmonary, reproductive, and digestive systems.1 

Mutations to the CFTR protein can be divided into five classes which differ in severity, with classes I-III generally being more severe than classes IV-V (see Table 1). Although differences in severity may be observed based on the class of mutation, it is important for clinicians to avoid solely using these classifications to define severity.2

 

Table 1: Classification of Cystic Fibrosis CFTR mutations2,3


Patients with CF may present with shortness of breath, productive cough, digital clubbing, nasal polyps, and pancreatic insufficiency. Pulmonary function tests may also indicate a reduced forced expiratory volume at 1 second (FEV1) due to pulmonary obstruction.4

According to the Canadian Cystic Fibrosis Registry 2020 annual report, a total of 4,332 Canadians are affected by CF attributing to 1 in every 3,600 live births.5 It is estimated that the current median life expectancy of patients with CF in Canada is 55.4 years.5 Early diagnosis and treatment of CF is a crucial component of long-term survival.Current diagnostic guidelines recommend that patients presenting with any of the following undergo a sweat chloride test to screen for CF6:
  • Positive newborn screening result
  • Signs and/or symptoms of CF
  • Family history of CF (e.g., siblings diagnosed with CF)

Sweat chloride testing is regarded as the gold standard screening method for CF. Using pilocarpine ionophoresis, the test quantifies the amount of chloride present in the sweat which can be used to aid in the diagnostic process (see table 2). Due to the dysfunction of the CFTR protein, patients with CF tend to present with elevated sweat chloride concentrations.6


Table 2: Sweat chloride test result interpretation6,7

 

Management of CF: Therapeutic options 

At present, there is no available cure for CF, however several therapeutic products can be used to help manage the disease by increasing airway clearance or partially restoring CFTR function. Patients with CF may also require nutritional support such as high calorie diets, fat soluble vitamin supplementation, and pancreatic enzyme supplementation.1

Therapies aimed at increasing airway clearance help patients improve their overall lung function and reduce the risk of pulmonary infections. A combination of non-pharmacologic airway clearance techniques, such as postural drainage (conventional chest physiotherapy), active cycle breathing techniques, airway oscillating devices, and exercise8, along with pharmacologic therapies. In patients 6 years and older, the following sequence of administration is typically followed: bronchodilators, followed by mucolytics, then non-pharmacologic airway clearance techniques, then inhaled antibiotics.1,4

In addition to therapies aimed at increasing airway clearance, patients may also be treated using CFTR modulators which aim to partially restore CFTR function. Currently, 4 CFTR modulators are available in Canada, the newest of which being Trikafta® (ivacaftor/tezacaftor/elexacaftor) Trikafta® is a triple combination CFTR modulator new to the Canadian market for the treatment of CF in patients 6 years and older.9 The treatment is targeted at patients who have at least one CFTR gene mutation, specifically the F508del mutation which is estimated to affect up to 90% of patients with CF.4 Trikafta® works by binding to sites on the CFTR protein to increase its activity. When compared to baseline, patients receiving Trikafta® in clinical trials demonstrated a 14% increase in lung function. Of note, patients participating in the Trikafta® trials all continued on their existing bronchodilators, mucolytics, and inhaled antibiotics, but discontinued any other CFTR modulators.9 While CFTR modulators present many benefits to patients with CF, access to these medications remains limited due to cost barriers. First generation (Kalydeco®) and second generation (Orkambi®) modulators can be accessed through some provincial formularies; however, their access remains highly limited.

Table 3: Non exhaustive list of available therapeutic options in Canada for CF.4
 

In addition to pulmonary complications such as respiratory insufficiency, patients with CF may experience non-pulmonary complications. Examples of these complications include CF-related diabetes, pancreatic insufficiency, and osteoporosis. Due to the prevalence of complications among patients with CF, it is important that clinicians implement effective screening and preventative strategies in their care plans of patients with CF.14 

The role of pharmacists and pharmacy technicians in CF management

Due to the nature of the condition, it is integral that patients are adherent to their CF medication regimens to help prevent hospitalization and further complications. It is estimated that patients with CF are prescribed an average of 10 medications for the management of their condition. Pharmacists can play an integral role in the medication management of patients with CF to help improve adherence. A study conducted at the Intermountain Primary Children’s Hospital in the Utah found that pharmacist intervention resulted in nearly a 3-fold increase in adherence to Dornase alpha and was associated with a decrease in hospitalization rate due to non-adherence.15 In addition, the inclusion of pharmacy technicians in CF clinic specialty pharmacies resulted in reduced wait times for specialty medications through timelier deliveries. The improved efficiency of medication delivery also resulted in a decreased need for patients to utilize multiple pharmacies to access their medications.11 Overall, integrating members of the pharmacy team into the management of patients positively impacts patient care through timely access to specialty medications (through decreased delivery times and time required for prior authorization), improved patient education/adherence, and reduced hospitalization.16

 

References

1. Wright CC, Vera Y. Cystic Fibrosis. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. Pharmacotherapy: A Pathophysiologic Approach, 11e. McGraw Hill; 2020. Accessed September 15, 2022. https://accesspharmacy.ca 
2. Katkin JP. Cystic Fibrosis: Genetics and pathogenesis. In: UpToDate. UpToDate; 2022. Accessed September 23, 2022. www.uptodate.com 
3. Types of CFTR mutations. Cystic Fibrosis Foundation. Accessed September 23, 2022. https://www.cff.org/research-clinical-trials/types-cftr-mutations#conduction-mutations 
4. Tang A, Crawley A. Cystic Fibrosis: Drug comparison chart. January 2022. Available from www.rxfiles.ca 
5. The Canadian Cystic Fibrosis Registry. 2020 Annual report. Published February 2022. Accessed September 21, 2022. https://www.cysticfibrosis.ca/registry/2020AnnualDataReport.pdf  
6. Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation [published correction appears in J Pediatr. 2017 May;184:243]. J Pediatr. 2017;181S:S4-S15.e1. doi:10.1016/j.jpeds.2016.09.064 
7. Katkin JP. Cystic Fibrosis: Clinical manifestations and diagnosis. In: UpToDate. UpToDate; 2022. Accessed September 20, 2022. www.uptodate.com 
8. Wilson LM, Morrison L, Robinson KA. Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2019;1(1):CD011231. Published 2019 Jan 24. doi:10.1002/14651858.CD011231.pub2
9. Vertex Pharmaceuticals. Trikafta product monograph. Available at: https://pi.vrtx.com/files/Canadapm_trikafta_en.pdf 
10. Ipratropium (Oral Inhalation). In Lexi-Drugs. Lexi-Comp, Inc. Updated October 25, 2022. Accessed November 18, 2022. https://online.lexi.com
11. Levofloxacin (Oral Inhalation). In Lexi-Drugs. Lexi-Comp, Inc. Updated November 10, 2022. Accessed November 18, 2022. https://online.lexi.com
12. Tobramycin (Oral Inhalation). In Lexi-Drugs. Lexi-Comp, Inc. Updated November 2, 2022. Accessed November 18, 2022. https://online.lexi.com
13. Aztreonam (Oral Inhalation). In Lexi-Drugs. Lexi-Comp, Inc. Updated September 19, 2022. Accessed November 18, 2022. https://online.lexi.com
14. Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med. 2019;13(1):23-38. doi:10.1080/17476348.2019.1552832
15. Zobell JT, Schwab E, Collingridge DS, Ball C, Nohavec R, Asfour F. Impact of pharmacy services on cystic fibrosis medication adherence. Pediatr Pulmonol. 2017;52(8):1006-1012. doi:10.1002/ppul.23743
16. Grant JJ, McDade EJ, Zobell JT, Young DC. The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. Pediatr Pulmonol. 2022;57 Suppl 1:S17-S39. doi:10.1002/ppul.25613

Latest News

November 21, 2022
Clinical Pearls: Cystic Fibrosis

Latest News

CSHP Foundation Welcomes New Trustees

November 16, 2022
 

Pharmacist Trustee

Jennifer Jupp was recently appointed Pharmacist Trustee of the CSHP Research and Education Foundation. Jennifer replaces Trustee Sheryl Zelenitsky, who completed her six-year term (including one year as Chair) on the Foundation’s Board.

Jennifer Jupp graduated from the University of Alberta in 2000, obtaining her Board Certification in Oncology in 2007 and her Master of Arts in Healthcare Leadership in 2022. Jennifer has been a Pharmacy Clinical Practice Leader with Provincial Pharmacy Services at Alberta Health Services, since 2011. 

As a clinical practice leader, she provides clinical practice support and mentorship for pharmacist teams in pediatric and adult oncology. More recently, Jennifer has been supporting the provincial implementation of an electronic health record by providing project leadership to align clinical practice and provincial initiatives with technical functionality.

Jennifer is strongly committed to advancing the practice of clinical pharmacists within the multidisciplinary team and enjoys participating in practice-based research. Jennifer is the current Chair of the International Society of Oncology Pharmacy Practitioners Research Committee and continues to be involved with CSHP AB and the Canadian Association of Pharmacy in Oncology.

 
Public Member Trustee

Dara Willis was recently appointed Public Member Trustee of the CSHP Research and Education Foundation. Dara replaces outgoing Public Member Trustee Marlo Taylor, who completed her six-year term on the Foundation’s Board.  

Dara Willis is a strategic communications and marketing professional with 20+ years of experience supporting clients in various industries, with a focus in healthcare, through complex and regulated communications challenges. 
With clients ranging from large-scale pharmaceutical companies, industry associations and patient stakeholder groups, Dara has had a front row seat to witness and respond to the dramatic changes that have impacted Canada’s healthcare system. 

Dara recognizes the challenges that organizations face when they are looking to educate and reinforce positions and policies, regardless of the audience and has spent the better part of her career helping clients formulate their position on topics of interest (including potential issues) and help develop communications programs and initiatives that are strategic and effective in their goals. 

She has also worked extensively with stakeholder groups and foundations in their pursuit of funding for research and educational programs and is unique in that she has supported clients from both sides of the funding paradigm – pharmaceutical companies looking to partner with stakeholder groups for specific initiatives and stakeholder groups looking to break free from the crowded funding landscape to bring programs of interest forward to potential funding organizations. 

Dara has a Bachelor of Arts (Honours) with a speciality in Archaeology from McMaster University, and a post-graduate certificate in Public Relations from Humber College. 

 
 
 

Introducing the 2022-2023 Foundation Board


Pharmacists Trustees
Michael LeBlanc (Chair)

Heather Kertland (Past Chair)
Sharon Seow
Nkem Iroh
Jennifer Jupp

Industry Trustees
Mark Lachovsky
Sherry Piersol

Public Member Trustee
Dara Willis

Foundation Chief Administrator
Jody Ciufo (CSHP CEO)

A special thank you to
Sheryl Zelenitsky (outgoing Pharmacist Trustee)
Marlo Taylor (outgoing Public Member Trustee) 

For the complete biographies and photos of all current Foundation Trustees, please visit the Foundation webpage here.

 

November 16, 2022
CSHP Foundation Welcomes New Trustees

Latest News

2022 AGM Weekend Highlights 

November 8, 2022
 
CSHP had a busy and extended AGM weekend with a combined joint-symposium with l'Association des pharmaciens des établissements de santé du Québec (A.P.E.S.), multilateral meetings with Indigenous Pharmacy Professionals of Canada (I.P.P.C.), and our own Annual General Meeting.  

Here are some of the highlights. 

IPPC (Indigenous Pharmacy Professionals of Canada) 

Thank you to the Indigenous Pharmacy Professionals of Canada co-chairs Amy Lamb and Jaris Swidrovich for their presence at multi-lateral meetings as well as for Amy’s address at our Annual General Meeting. 

We held these meetings along with our colleagues from CPhA, NAPRA, AFPC, CPRB and Pharmacy Examining Board of Canada. The goal of these meetings was to introduce IPPC’s mandates then determine ways that we could all support Indigenous Pharmacy Professionals and patients in Canada. The representing organizations also shared their ongoing work relating to Indigenous pharmacy and brainstormed how IPPC fits in to their future plans.  

Your crucial insight on respect, reverence, sustainability, and family strength left us all inspired to inspect our day-to-day approach. We look forward to our ongoing collaboration and we will continue to spread the word about this new community built to support Indigenous pharmacy professionals. 

Pandemic Takeaways for Hospital Pharmacy 

On Oct. 28 and 29 we held our first-ever joint symposium between A.P.E.S. and CSHP after many years of being strategic allies. The symposium covered a topic that profoundly affected and still affects us all -   both professionally and personally- the COVID-19 Pandemic. The purpose of this event was to reflect, regroup, and reassess how we dealt with this pandemic and how we can best deal with future ones. Thanks to our amazing speakers and guests, we did just that! 

AGM (Annual General Meeting)

The CSHP 2022 Annual General Meeting was held at the Four Points by Sheraton, Gatineau-Ottawa, this past weekend. The Board of Directors and members alike were provided with a thorough update on CSHP, and were given a year in review presentation and voted on critical issues for the Society. 

At these meetings, the board approved a motion to amend articles 5, 8 and 9 of our Articles of Continuance. In simpler terms, article 5 saw the change to the minimum and maximum number of directors to 13 and 25, respectively. Article 8 clarified that there is only one class of members and eliminated any references to Branches since these are covered in our bylaws. Finally, article 9 touches on if CSHP were to dissolve, the remaining assets would be distributed to like-minded organizations across Canada. 

For CSHP Bylaws, a motion was made to make substantive changes to bylaw 1. Namely, these changes include the number of members required to establish a new branch as well as updating wording, definitions, powers, and rights seen throughout this bylaw.  

We also added some fresh faces to the board and saw some shifting among positions including: 
 
  • President Sean Spina (Victoria, BC) 
  • Past President Zack Dumont (Regina, SK)  
  • President Elect Ashley Walus (Winnipeg, MB)  
  • Nova Scotia Delegate Kimberley Abbass (Halifax, NS) 
  • Ontario Delegate Andrea Beaman (Toronto, ON)
  • British Columbia Delegate Karen Dahri (Vancouver, BC) 

Board Updates 

In addition to the additions made to the board, CSHP also bid adieu to four incredible members of our Board of Directors. Please join us in thanking departing delegates Arden Barry (BC), Alanna McQuaid (NS), and Vivian Lee (ON). Special thanks and gratitude are due to Past President Tania Mysak who led CSHP through the unprecedented COVID-19 pandemic and the upheaval it caused in our Society, our hospitals, and our homes. Thank you, Tania, for your dedication to CSHP and to hospital pharmacy.  

Please visit the board page to see all current members of the Board of Directors! 

Hospital and Not-for-Profit Supporters

The board approved a new membership supporter category, Not-for-Profit Supporters, which will provide these organizations (ex: colleges, advocacy organizations, trade unions, government agencies, etc.) a discounted price for their supporter membership. Additionally, they voted to revamp the Hospital Supporter category. There will be a shift from the title Corporate Hospital Supporter to simply Hospital Supporters. This change will also refocus this supporter-ship to being more about the products and services that CSHP offers. There was also a change to Hospital Supporter fees. These changes provide an opportunity for these organizations to benefit further from supporting the Society, starting with special pricing for CSHP Hospital Pharmacy 101 seen here. To learn more about Hospital & Not-for-Profit Supporters, click here.

 

November 08, 2022
2022 AGM Weekend Highlights

Latest News

Supporting the future of hospital pharmacy 

November 8, 2022


"The Canadian Society of Hospital Pharmacists (CSHP) have always been committed to the advancement of hospital pharmacy, so it is crucial to support the next generation: our Student Supporters, Members-in-Training and new Members. We want the future of the profession to feel that their Society is working hard to reflect their values, their ambitions, and their dreams — so they can contribute fully to the best possible patient outcomes.” - Jody Ciufo, Chief Executive Officer of CSHP 

CSHP is proud to invest in the many stages of student education and pharmacy residency. 

Flocking to residency

Pharmacy Residency Application Roadmap Program  - 82 Registrations
 This CSHP course offers didactic sessions and take-home coursework focused on the intricacies of residency programs and applications. After welcoming 125 people to our free module, “Making the pharmacy residency choice”, over the summer, we had 82 registrations for the programs with 74 also taking part in the mock interview. We are pleased that participants continue to be able to apply their learnings in their applications. 

Pharmacy Residency Application and Matching Service (PRAMS) -  313 Registrations
 The Pharmacy Residency Application and Matching Service (PRAMS) is a national application and matching service that provides a coordinated process to help match pharmacy residency applicants with positions at hospital pharmacy residency programs across Canada. The Canadian Pharmacy Residency Board (a semi-autonomous body of CSHP) runs PRAMS, in addition to conducting accreditation surveys, issuing accreditation awards, establishing accreditation policies and procedures, and developing and promoting education and research initiatives related to residency programs and residency training. This fall, we had a total of 445 applicants, with 313 applicants completing all the necessary requirements to make it through to the interview stage. Interviews will take place over the fall months, with the Match taking place in early January. In total, there are 133 residency positions available for the 2023-2024 residency year. 

CSHP loves CAPSI

“While the PharmD programs aim to balance teaching us all aspects of the pharmacy profession, sometimes students want more exposure to certain areas. CSHP focuses on hospital practice which allows us a link to hospital-specific resources and those working directly in the field for students who have a strong desire to work in the hospital sector.” - Madison Wong, CAPSI President-Elect 

CAPSI
CSHP has held a long-term working relationship with this student-run national organization, composed of over 4,000 members committed to their individual professional development and to the advancement of the pharmacy profession. 

CAPSI representatives  
As part of their mission to advocate for pharmacy students' interests in the country's pharmacy schools, the CAPSI National Council is comprised of executives and local representatives that help with the creation and planning of major developmental opportunities. CSHP frequently meets with CAPSI representatives to collaborate on Professional Development Week, the Evidence-Based Practice Competition, and Pharmacy Appreciation Month.  

Evidence-Based Medicine Competition 
CAPSI developed the Evidence-Based Practice Competition with CSHP in 2013. CSHP has been providing support for the competition, such as writing hospital patient cases. The purpose of this competition is to challenge members to apply current literature and guidelines to therapeutic recommendations and use their clinical knowledge to do so. This competition has also helped students to improve their collaboration and communication skills. 

CAPSI + CSHP Student Award 
This award is presented to an undergraduate pharmacy student who exhibits the traits of a future hospital pharmacy practitioner through participation in the education of healthcare practitioners, the public or patients, and/or through voluntary participation in CSHP activities.  

Professional Development Week (PDW) 
During this conference, students from across the country apply their practical skills and expand their knowledge of healthcare topics. CPRB and CSHP proudly sponsor a booth every year and we have a wonderful time engaging with students as they take their learning outside of the classroom.

Developing passionate leaders now

“Being the National Student Delegate for CSHP has been a great experience so far as I have been able to liaise between CSHP and pharmacy students across Canada to inform them and teach them about hospital pharmacy. CSHP provides so many learning opportunities and conferences for pharmacy students and I am so glad I get to promote these opportunities to pharmacy students across Canada.” - Abby Krupski, National CSHP Student Delegate  

National Student Delegate
Representing pharmacy students across the country, the CSHP Board of Directors’ National Student Delegate helps shape and lead the future of hospital pharmacy in Canada. They are the voice of pharmacy students and are a voting member on the Board. They also serve as a liaison to CAPSI and CSHP school representatives. 

CSHP Branch student symposia
CSHP Branch and pharmacy school representatives host student symposia to introduce second-year students to what CSHP does and what hospital pharmacy looks like. CSHP Branches work with the national office on funding and materials for these engaging and informative events. 

Curriculum feedback 
Earlier this year the Canadian Council for Accreditation of Pharmacy Programs (CCAPP) was reviewing accreditation standards and requested feedback from CSHP. While combing through the standards, we were able to provide feedback that reflected the COVID-19 pandemic’s impact on healthcare and the significant changes in pharmacy education. 

Ongoing student placements at CSHP 
CSHP’s Professional Practice team has been fortunate to be preceptors for seven students, just this year, from our partner institutions at the University of Waterloo, the University of Saskatchewan, the University of British Columbia, and the University of Toronto. During their non-clinical placement with us, students not only take on critical projects like writing Clinical Pearls or Resource Spotlights but also participate in CSHP's advocacy and research activities under the mentorship of the Professional Practice Team. 

Association of Faculties of Pharmacy of Canada (AFPC)
The Association of Faculties of Pharmacy of Canada (AFPC) is the national voice for academic pharmacy, providing leadership and resources for faculty members across Canada. CSHP has worked closely with AFPC, including writing a letter of support for the creation of the University of Ottawa’s faculty of pharmacy that will start accepting students in September 2023. 

Faculties  
CSHP also proudly works with the individual universities of AFPC (Dalhousie University, Memorial University of Newfoundland, Université de Montréal, Université Laval, University of Alberta, University of British Columbia, University of Manitoba, University of Saskatchewan, University of Toronto, and University of Waterloo) by maintaining a presence with their respective Pharmacy councils, assisting Academic advisors, and having student liaisons. 

Summary

Not only are we excited about continuing our support of students, but we are also looking forward to discovering new ways to support our Student Supporters and Members-in-Training. There are many volunteers to thank for their hard work in making sure that the future of hospital pharmacy continues to be excellent. In addition, we have the following individuals who work for—or closely with— CSHP to help serve students even better: 

CSHP student program staff lead – Hira Tauqeer 
CSHP National Board student delegate – Abby Krupski 
Current CAPSI president – Christine Vaccaro 
CPRB (Canadian Pharmacy Residency Board) Coordinator – Vanessa Glasby 
CSHP National Awards program administrator – Robyn Rockwell
CAPSI evidence-based medicine competition coordinator & student preceptor – Minh-Hien Li 
Student preceptor – Kiet-Nghi Cao 

November 08, 2022
Supporting the future of hospital pharmacy

CSHP Video

The Value of Hospital Pharmacists

Every day, hospital pharmacy teams improve your health and save our hospitals money. They are trusted and valued members of the healthcare team.

Learn More